viral
pneumonia
caus
respiratori
virus
rv
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
among
respiratori
viral
infect
rvi
caus
respiratori
syncyti
viru
rsv
influenza
human
parainfluenza
viru
hpiv
associ
higher
risk
progress
pneumonia
howev
clinic
cours
rvi
depend
type
viru
also
immunolog
statu
host
sever
seri
identifi
risk
factor
proxim
transplant
deplet
cord
blood
mismatch
transplant
presenc
diseas
gvhd
use
glucocorticoid
lymphopenia
predict
poorer
immunodefici
score
index
develop
patient
rsv
infect
high
score
predict
progress
upper
respiratori
tract
infect
urti
pneumonia
need
ventil
recent
isi
shown
applic
influenza
infect
well
significantli
higher
incid
pneumonia
vs
studi
retrospect
review
recipi
center
respiratori
symptom
posit
polymeras
chain
reaction
pcr
result
rv
primari
aim
studi
evalu
applic
retrospect
cohort
recipi
rvi
includ
rvi
secondari
aim
describ
epidemiolog
rvi
recipi
transplant
center
tropic
infect
tend
occur
current
avail
literatur
larg
origin
center
temper
climat
retrospect
review
patient
underw
hospit
decemb
march
electron
medic
record
patient
review
rv
pcr
perform
episod
rvi
score
use
neutrophil
lymphocyt
score
age
year
score
abl
condit
gvhd
corticosteroid
use
prior
day
within
day
hsct
score
total
score
inform
treatment
outcom
collect
patient
follow
till
may
death
whichev
earlier
retrospect
analysi
approv
hospit
institut
review
board
made
slight
modif
publish
definit
urti
viral
urti
defin
presenc
respiratori
symptom
eg
cough
coryza
sore
throat
posit
rv
pcr
result
throatnasopharyng
swab
without
hypoxia
new
infiltr
chest
imag
viral
pneumonia
defin
posit
rv
pcr
result
throatnasopharyng
swab
bronchoalveolar
lavag
bal
new
infiltr
chest
imag
taken
day
day
posit
rv
pcr
patient
initi
present
viral
urti
subsequ
develop
pneumonia
defin
progress
pneumonia
caus
could
found
progress
howev
bacteri
fungal
isol
respiratori
sampl
laboratori
clinic
evid
suggest
activ
bacteri
fungal
infect
eg
posit
blood
cultur
progress
attribut
rvi
bronchoscopi
done
bal
fluid
routin
sent
gram
stain
aerob
anaerob
cultur
fungal
smear
cultur
bacilli
smear
mycobacteri
cultur
stain
pneumocysti
jirovecii
galactomannan
rv
pcr
panel
cytomegaloviru
herp
simplex
viru
cultur
legionella
pneumophilia
cultur
antigen
detect
immunofluoresc
patient
may
episod
rvi
prolong
viral
shed
rvi
episod
caus
viru
score
new
episod
rvi
defin
posit
pcr
differ
viru
posit
pcr
viru
least
week
document
clearanc
swab
posit
two
virus
involv
either
rsv
influenza
score
rsv
influenza
infect
respect
virus
individu
score
nosocomi
infect
defin
posit
swab
taken
symptom
develop
hour
admiss
within
hour
discharg
hospit
mortal
occur
within
month
viral
pneumonia
analyz
caus
death
direct
causal
implic
patient
rvi
primari
event
without
incident
analysi
outcom
patient
treat
specif
antivir
drug
oseltamivir
ribavirin
treatment
consid
delay
initi
day
diagnosi
decemb
octob
rv
multiplex
pcr
perform
use
seeplex
ace
detect
kit
seegen
south
korea
follow
manufactur
instruct
kit
detect
rv
human
adenoviru
adv
human
metapneumoviru
human
coronaviru
hcov
hcov
influenza
b
virus
rsv
b
human
rhinoviru
hrhv
ab
octob
august
seegen
anyplex
ii
seegen
south
korea
use
august
march
seegen
anyplex
ii
seegen
south
korea
use
latter
two
kit
detect
respiratori
virus
includ
virus
detect
seeplex
kit
addit
virus
hpiv
hrhv
c
enteroviru
human
bocaviru
hbov
overal
surviv
estim
use
approach
cumul
incid
first
rvi
episod
plot
death
compet
risk
fisher
exact
test
use
investig
associ
risk
group
low
moder
high
outcom
measur
includ
incid
pneumonia
subsequ
progress
pneumonia
need
ventil
mortal
rvi
episod
involv
rsv
influenza
hrhv
hpiv
hcov
adv
receiv
oper
characterist
roc
analysi
conjunct
logist
regress
use
assess
predictor
pneumonia
infect
caus
virus
total
patient
underw
studi
period
adult
patient
year
age
among
patient
manifest
rvi
underw
rv
pcr
test
least
one
posit
pcr
result
recipi
never
rvi
manifest
undergo
rv
pcr
test
tabl
show
characterist
three
group
patient
rvi
occur
sporad
throughout
year
peak
see
figur
distribut
type
rvi
across
month
year
patient
rvi
episod
patient
episod
patient
episod
patient
episod
therefor
altogeth
total
episod
rvi
detect
variou
type
virus
includ
rsv
b
rsv
influenza
b
hrhv
hpiv
hcov
adv
metapenumoviru
hbov
human
enteroviru
first
preval
compris
rvi
episod
episod
mix
infect
two
virus
three
virus
detect
sampl
tabl
show
distribut
clinic
associ
viru
cumul
incid
develop
first
episod
rvi
day
transplant
month
month
year
post
hsct
figur
rvi
episod
episod
manifest
pneumonia
present
episod
initi
manifest
urti
subsequ
progress
pneumonia
give
total
episod
pneumonia
shown
tabl
potenti
virul
virus
rsv
influenza
adv
associ
high
incid
pneumonia
episod
respect
howev
note
even
seemingli
benign
virus
hcov
hrhv
also
associ
incid
pneumonia
episod
respect
expect
influenza
rvi
consist
treat
influenza
episod
treat
oseltamivir
two
untreat
episod
one
patient
diagnos
mani
day
urti
symptom
treatment
deem
use
present
acut
respiratori
failur
septic
shock
caus
bacteri
process
throat
swab
return
posit
influenza
posthum
episod
influenza
present
pneumonia
diagnosi
influenza
urti
episod
present
progress
pneumonia
whether
oseltamivir
prevent
progress
pneumonia
analyz
except
episod
treat
case
progress
pneumonia
present
urti
oral
ribavirin
use
treat
episod
rsv
treatment
ribavirin
seem
impact
progress
pneumonia
episod
present
urti
two
episod
rsv
urti
untreat
treat
late
progress
pneumonia
episod
rsv
urti
treat
earli
progress
pneumonia
fisher
exact
test
among
episod
pneumonia
episod
requir
mechan
ventil
total
death
occur
within
week
viral
pneumonia
tabl
deem
directli
attribut
viral
pneumonia
includ
rsv
hpiv
primari
caus
death
death
within
week
document
rvi
occur
n
context
multipl
activ
complic
gvhd
neutropen
sepsi
failur
instanc
extent
rvi
contribut
toward
death
difficult
ascertain
therefor
surpris
differ
surviv
observ
among
patient
rvi
patient
patient
never
rvi
figur
primari
object
explor
applic
rvi
analyz
data
patient
rvi
appli
base
episod
classifi
low
risk
score
moder
risk
score
high
risk
score
use
fisher
exact
test
risk
score
show
signific
associ
pneumonia
rvi
rsv
influenza
hcov
adv
tabl
associ
found
hrhv
hpiv
associ
explor
prognost
valu
rvi
episod
roc
analysi
predict
pneumonia
take
virus
togeth
roc
analysi
show
posit
predict
valu
ppv
neg
predict
valu
npv
poorli
predict
analyz
specif
virus
ppv
npv
rsv
influenza
adv
hpiv
caus
pneumonia
area
roc
curv
respect
figur
predict
pneumonia
hcov
hrhv
roc
analysi
done
predict
need
mechan
ventil
death
owe
small
number
two
outcom
indic
studi
explor
applic
patient
rvi
caus
broad
rang
differ
virus
review
data
also
gener
first
time
inform
rvi
patient
tropic
center
main
thrust
studi
see
appli
rsv
rvi
predict
valu
advers
outcom
find
ppv
npv
predict
pneumonia
cutoff
valu
respect
rsv
influenza
adv
hpiv
practic
relev
exampl
patient
urti
symptom
high
seen
clinic
prudent
lower
threshold
chest
perhap
admiss
hospit
closer
observ
rvi
establish
drug
therapi
isi
also
give
guidanc
earli
institut
treatment
find
predict
valu
rvi
wholli
surpris
compon
index
shown
individu
risk
factor
advers
outcom
differ
studi
infect
differ
rvi
lymphopenia
exampl
emerg
risk
factor
advers
outcom
sever
steroid
independ
risk
factor
progress
pneumonia
review
hpiv
infect
absenc
factor
index
give
potenti
applic
beyond
rsv
inde
group
develop
found
similarli
use
appli
patient
modest
number
patient
adv
hpiv
rvi
observ
similar
pattern
two
virus
well
immunodefici
score
found
predict
pneumonia
hrhv
hcov
seri
could
result
inadequ
number
case
rel
lack
opportunist
potenti
two
virus
even
immunocompromis
patient
hrhv
commonest
caus
common
well
common
viru
found
milano
et
calcul
cumul
incid
hrhv
day
studi
hrhv
infect
infrequ
associ
pneumonia
hand
ghosh
et
describ
hsct
recipi
develop
hrhv
infect
period
among
develop
pneumonia
die
ison
et
found
hrhv
detect
bal
fluid
hsct
recipi
associ
high
rate
mortal
seri
episod
hrhv
pneumonia
death
occur
within
week
hrhv
pneumonia
amid
transplant
complic
similar
profil
observ
hcov
pneumonia
seen
case
includ
episod
requir
mechan
ventil
observ
highlight
even
rv
low
virul
may
associ
complic
immunocompromis
host
remind
us
case
rvi
patient
taken
seri
also
review
data
treatment
outcom
rsv
influenza
controversi
exist
use
oseltamivir
influenza
immunocompet
howev
gener
accept
immunocompromis
person
receiv
seri
episod
influenza
pneumonia
present
pneumonia
present
episod
influenza
urti
progress
skew
present
prevent
us
studi
use
oseltamivir
prevent
progress
pneumonia
rsv
rsv
pneumonia
recipi
associ
signific
systemat
review
conclud
ribavirin
aerosol
oral
intraven
probabl
data
fail
show
earli
treatment
within
day
posit
pcr
result
could
prevent
progress
pneumonia
howev
could
result
select
bia
untreat
patient
outpati
well
symptom
mani
day
use
oral
oppos
aerosol
ribavirin
unavail
local
could
caus
failur
prevent
progress
made
observ
analysi
epidemiolog
influenza
rsv
known
differ
tropic
temper
area
singapor
influenza
rsv
occur
small
peak
period
correspond
southern
northern
hemispher
winter
data
consist
trend
rvi
occur
sporad
cohort
patient
figur
nosocomi
viral
infect
known
occur
hsct
unit
rather
larg
percentag
nosocomi
hpiv
adv
case
reflect
outbreak
two
virus
respect
gratifi
one
case
influenza
nosocomi
origin
possibl
owe
annual
influenza
vaccin
hospit
staff
receiv
nevertheless
nosocomi
rate
might
lower
easier
access
singl
room
patient
shortag
singl
room
reserv
posit
pressur
singl
room
patient
undergo
transplant
neutropen
also
note
incid
rvi
hsct
report
literatur
differ
greatli
among
studi
suspect
relat
larg
diagnost
method
martino
et
use
cultur
method
diagnos
rvi
pcr
metapneumoviru
found
rate
period
furthermor
report
make
mention
coronavirus
wolfromm
et
use
multiplex
pcr
report
hsct
patient
develop
rvi
cumul
incid
use
pcr
kit
detect
rang
virus
akin
ambriosini
et
found
incid
upper
respiratori
sampl
survey
figur
almost
like
therefor
incid
rvi
unusu
high
studi
limit
absenc
prospect
protocol
confid
complet
captur
case
nevertheless
two
oper
factor
enabl
high
captur
rate
geograph
small
loss
rariti
hsct
patient
advis
return
directli
outpati
clinic
problem
aris
guidelin
close
follow
give
us
confid
attribut
symptom
viral
infect
also
low
threshold
test
rv
singl
symptom
eg
coryza
trigger
one
problem
struggl
definit
rvi
caus
death
mainli
littl
guidanc
avail
literatur
adher
publish
remain
concern
publish
statement
lack
summari
review
rvi
recipi
verifi
applic
patient
rsv
addit
influenza
adv
hpiv
rvi
predict
risk
develop
pneumonia
find
use
beyond
clinic
manag
may
also
use
stratif
clinic
trial
novel
antivir
document
high
associ
hrhv
hcov
pneumonia
high
incid
pneumonia
caus
rvi
incid
need
mechan
ventil
death
testifi
unmet
need
effect
antivir
therapi
rvi
group
immunocompromis
host
bht
ycl
design
project
lw
collect
data
ja
conduct
statist
analysi
lw
bht
ycl
perform
data
interpret
draft
cd
ytg
sg
ah
wh
fl
lo
ttt
involv
laboratori
clinic
manag
patient
author
declar
conflict
interest
